Muna Bhanji - 29 Jan 2025 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
Director
Signature
/s/ James Basta, attorney-in-fact
Issuer symbol
NTLA
Transactions as of
29 Jan 2025
Net transactions value
-$2,642
Form type
4
Filing time
31 Jan 2025, 16:17:16 UTC
Previous filing
17 Jun 2024
Next filing
01 May 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Sale $2,642 -265 -1.3% $9.97 19,468 29 Jan 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported sale of 265 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 27, 2024.